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Background: Gastrointestinal stromal tumors (GISTs) comprise < 1% of all gastrointestinal (GI) tumors,
but GISTs are the most common mesenchymal tumors of the GI tract. Dramatic changes in clinical
practice have been observed in the last decade. This review highlights the overall management of GIST
and its recent developments.
Method:We identiﬁed literature by searching Medline and PubMed from January 1995 to December 2011
using the keywords “gastrointestinal stromal tumors”, “GIST”, “imatinib” and “tyrosine kinase inhibitor”.
Additional papers were identiﬁed by a manual search of the references from the key articles. There were
no exclusion criteria for published information to the topics.
Results: For localized primary GISTs, surgical resection is the mainstay of therapy. The 5-year survival rate
after complete resection of GISTs is approximately 50%e65%. Many factors including tumor size, mitotic
rate, tumor location, kinase mutational status and occurrence of tumor rupture have been extensively
studied and proposed to be predictors of survival outcomes. Adjuvant imatinib is proposed as an option
for those patients with a substantial risk of relapse. Unresectable metastatic or recurrent GIST can be
treated with a tyrosine kinase inhibitor, imatinib, with a remarkable response (50%e70%) and prolonged
survival (median progression-free survival: 18e20 months; median overall survival: 51e57 months). The
standard approach in the case of tumor progression on 400 mg once per day is to increase the imatinib
dose to 400 mg twice per day as permitted by toxicity. Use of a second-line targeted agent, sunitinib, in
patients with advanced GIST who fail (or are intolerant of) imatinib therapy is advised.
Conclusion: Treatment for GISTs has become increasingly complex because of the growing understanding
of its biology. A multidisciplinary team that includes radiologists, medical oncologists, pathologists, and
surgeons is paramount for the effective treatment of GIST.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Gastrointestinal stromal tumors (GISTs) comprise < 1% of all
gastrointestinal (GI) tumors, but GISTs are the most common
mesenchymal tumors of the GI tract. In the past, these tumors were
classiﬁed as leiomyomas, leiomyosarcomas, or leiomyoblastomas.
With the advent of immunohistochemistry and electron micros-
copy, GIST is recognized as a separate entity during the last decade.
The overall incidence including incidental small tumors, has been
estimated to be 6 to 20 per million.1e6 GISTs demonstrate a similar
distribution between men and women. Although GISTs have been
reported in patients of all ages, most patients are between 40 and: þ852 2637 7974.
.hk, josephlau@cuhk.edu.hk
ciates Ltd. Published by Elsevier Lt80 years old at the time of diagnosis, with a median age of 60e65
years.1e6 GISTs most commonly occur in the stomach (60%e70%),
followed by the small intestine (20%e30%), duodenum (4%e5%),
rectum (4%e5%), colon (<2%) and esophagus(<1%).5e9 On rare
occasions, GISTs develop outside the GI tract in the mesentery,
omentum, or retroperitoneum.5e10 1%e2% of GISTs occur in the
pediatric population which are thought to be fundamentally
different entities from adult GISTs. They are almost exclusively
gastric in origin and, unlike adult GISTs, are more common in girls.
For localized primary GISTs, surgical resection is the mainstay of
therapy. It is well known that advanced GIST can be treated with
a tyrosine kinase inhibitor imatinib (Gleevec; Novartis Pharma AG,
Basel, Switzerland), with a remarkable tumor response and pro-
longed survival. New second-line targeted agents are nowavailable.
Treatment for GISTs has also become increasingly complex because
of the growing understanding of biology of this tumor. Therefore,
a multidisciplinary team that includes radiologists, medicald. All rights reserved.
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effective treatment of GIST.
This review highlights the overall management of GISTs and its
recent developments. Pediatric GIST that requires specialized
management is not included in this review.
2. Methods
We identiﬁed literature by searchingMedline and PubMed from January 1995 to
December 2011 using the keywords “gastrointestinal stromal tumors”, “GIST”,
“imatinib” and “tyrosine kinase inhibitor”. Additional papers were identiﬁed by
a manual search of the references from the key articles. There were no exclusion
criteria for published information to the topics.
3. Pathology & immunohistochemistry
Primary GISTs are typically well-circumscribed, soft, friable and
often highly vascular in nature. GISTs often appear heterogeneous
due to necrosis or intratumoral hemorrhage. Large tumors may
show ulceration of the overlying mucosa. Microscopically, most
GISTs demonstrate 3 main histologic subtypes: spindle cell type
(most common), epithelioid type, and mixed spindle and epithe-
lioid type. More than 95% of GISTs are positive for the tyrosine
kinase receptor protein KIT, which is detected by the antibody
CD117. Other common markers are CD34 (60%e70%) and smooth
muscle actin (SMA) (30%e40%). They are typically negative for
desmin and S-100 protein (<5% positive). In contrast, leiomyomas
and leiomyosarcomas are positive for SMA and desmin, and nega-
tive for KIT and CD34, which helps to distinguish GISTs from other
mesenchymal tumors.11e15
In 1983, Mazur and Clark observed that gastric tumors lacked
ultrastructural and immunohistochemical evidence of smooth
muscle differentiation and ﬁrst introduced the term “stromal
tumor”.16 In 1998, Kindblom and his colleagues observed that GISTs
had immunomorphological similarities to the interstitial cells of
Cajal and proposed the term “gastrointestinal pacemaker cell
tumor”.17 That same year, Hirota and his colleagues discovered that
sequencing of c-kit complementary DNA, which encodes a proto-
oncogenic receptor tyrosine kinase (KIT), from ﬁve GISTs revealed
mutations in the region between the transmembrane and tyrosine
kinase domains.18 All the corresponding mutant KIT proteins were
constitutively activated without the KIT ligand. GISTs are believed
to arise from the interstitial cells of Cajal, components of the
intestinal autonomic nervous system that serve as intestinal
pacemakers. These works supported the hypothesis that GIST may
indeed develop from stem cells that differentiate toward the
interstitial cells of Cajal phenotype and conﬁrmed KIT as an accu-
rate diagnostic tool for GIST.
Immunohistochemical analysis has demonstrated that nearly all
GISTs (approximately 85%) contain activating mutations in KIT,
which leads to constitutive activation of KIT and its tyrosine kinase
function. This receptor, the product of the proto-oncogene c-kit
(located on chromosome 4q11q12), can be detected by immuno-
histochemical staining for CD117. KIT is involved in many cellular
functions, including cell differentiation, growth, and survival.
Binding of KIT to its ligand leads to dimerization and subsequent
autophosphorylation of KIT, which initiates a cascade of intracel-
lular signaling leading to adhesion, differentiation, proliferation,
and tumorigenesis. Several mutations have been described. Acti-
vatingmutations of exon 11 of KIT are themost commonmutations.
Others include exons 9, 13, and 17. About 5% contain mutations in
platelet-derived growth factor receptor-alpha (PDGFRa). KIT and
PDGFRa mutations are mutually exclusive. The remainder of GISTs
do not contain identiﬁable mutations in either of these two
receptor kinases, otherwise known as ‘‘wild-type’’ GIST (10%e
15%).19e21 Current data suggests that mutational status has bothprognostic signiﬁcance and impact on response to tyrosine kinase
inhibitors therapy, which will be discussed in greater detail later in
this review.
4. Presentation
The clinical presentation of patients with GIST varies depending
on the anatomic location of the tumor, the tumor size and its
aggressiveness. GISTs are highly vascular submucosal masses and
typically grow outward, away from the originating GI lumen. Small
tumors (<2 cm) are most commonly found incidentally during
endoscopy, cross-sectional imaging, or laparotomy/laparoscopy for
other indications. Most (70%) patients diagnosed with GIST have
vague symptoms, such as abdominal pain, GI bleeding from
a mucosal erosion, or an abdominal mass.22,23
5. Investigation
Initial workup should include a detailed history and a thorough
physical examination, followed by cross-sectional imaging to both
assess the extent of the primary tumor and evaluate potential sites
of metastatic disease, most commonly the liver and peritoneum.
Metastases to the lungs or other extra-abdominal locations are
usually seen only in very advanced diseases. Lymph node metas-
tases are rare, except in the pediatric population. CT (computed
tomography) scan is the imaging modality of choice for initial
evaluation, staging, and monitoring of treatment response in GIST.
GISTs are visualized as enhancing solid masses and tumor vessels
are often noted on contrast enhanced CT scan.24e26 Small GISTs
typically appear as well-deﬁned soft-tissue, relatively low-density
masses that appear relatively homogeneous on contrast enhanced
CT scan. When the masses are large, they are often heterogeneous
because of necrosis, hemorrhage, and myxoid degeneration.
Magnetic resonance imaging (MRI) is an alternative option and is
indicated for surgical planning in rectal GISTs, for evaluation of liver
lesions indeterminate on CT scan, and for cases in which CT scan is
contraindicated.27e30 On MRI, GISTs are generally well deﬁned; the
solid portions of the masses are typically of low- to intermediate-
signal intensity on T1-weighted images and high signal intensity
on T2-weighted images. As in CT scan, the tumors enhance after
injection of an intravenous contrast agent. Percutaneous biopsy is
not recommended because of the potential risk of peritoneal
seeding or tumor rupture, and is indicated only when treatment
would be altered.
Contrast-enhanced CT scan plays an important role in surveil-
lance and early detection of tumor recurrence or progression.24e26
After treatment, tumors become hypodense and their size may
gradually decrease and eventually stabilize. Recurrence or disease
progression is traditionally diagnosed by ﬁnding an increase in
tumor size or the development of new lesions at the site of previous
disease or by ﬁnding distant metastasis. 18Fluoro-deoxyglucose-
positron emission tomography (18FDG-PET) is also highly sensitive
and speciﬁc in detecting GISTs and evaluating their response to
treatment.31e33
6. Prognostic factors for malignant potential and recurrence
Unlike other GI malignancies, the behavior of GIST is difﬁcult to
predict based on histopathology alone. Many factors including
tumor size, mitotic rate, tumor location, kinase mutational status
and occurrence of tumor rupture have been extensively studied
and proposed to be predictors of survival outcomes, but tumor
size and mitotic rate are the two most widely accepted
indices.7,34e45
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In 2001, the National Institutes of Health (NIH) in the USA held
a conference of experts with the goal of developing a consensus
approach to diagnosis and morphologic prognostication of GIST.
One scheme for predicting the risk of recurrence or metastasis of
a surgically resected primary GIST was developed by consensus at
this meeting and was published by Fletcher et al. in 2002.39 Tumor
size and mitotic index were the foundation for this consensus
approach to risk stratiﬁcation of GISTs. In general, tumors < 5 cm
and particularly those < 2 cm have a lower risk of metastasis,
whereas tumors > 5 cm and particularly those > 10 cm have
a higher risk. Similarly, a mitotic rate of <5 mitoses per 50 high
power ﬁelds (HPF) portends a low risk of metastasis, whereas
mitotic rates > 5 per 50 HPF and particularly those > 10 per 50 HPF
predict a higher risk of metastatic disease. These 2 factors are
independent but mutually inﬂuential predictors and are combined
in the NIH guidelines.
6.2. The Armed Forces Institute of Pathology (AFIP)-Miettinen
staging system
The US AFIP prognostic criteria developed on the basis of
a meticulous assessment of two large series of patients followed up
for a median of about 15 yearsdaccount for tumor site and provide
a more detailed risk stratiﬁcation. They proposed guidelines that
incorporated anatomic location, separating the classical risk factors
of tumor size and mitotic count between gastric and small intes-
tinal origin.7 In general, gastric tumors have a more favorable
prognosis than the intestinal tumors with similar parameters.
Gastric GISTs < or ¼ 10 cm and < or ¼ 5 mitoses per 50 HPF have
a low risk for metastasis, whereas those with >5 per 50 HPF and
>5 cm in diameter have a high risk for metastasis. In contrast, all
intestinal GISTs >5 cm independent of mitotic rate have at least
moderate risk for metastases, and all>5 per 50 HPF have a high risk
for metastases. Intestinal GISTs < or ¼ 5 cm with < or ¼ 5 per 50
HPF have a low risk for metastases.
6.3. Memorial Sloan-Kettering cancer center (MSKCC) prognostic
nomogram
The MSKCC sarcoma team developed a nomogram to estimate
the probability of recurrence-free survival based on tumor size (a
continuous variable), location (stomach, small intestine, colon/
rectum, or other), and mitotic index (<5 or > or ¼ 5 per 50 HPF)
after surgery for 127 patients with primary GIST at MSKCC.40 The
nomogram was tested in patients from the Spanish Group for
Research on Sarcomas (n ¼ 212) and the Mayo Clinic, Rochester,
MN, USA (n ¼ 148). Risk scores associated with each factor are ﬁrst
added up; then, the predicted probability of 2-year and 5-year
recurrence-free survival can be read from the nomogram. The
nomogram was assessed by calculating concordance probabilities
and testing calibration of predicted recurrence-free survival with
observed recurrence-free survival.
6.4. Mutational status
More recent studies of GIST patients have focused on the effect
of mutational status on response to imatinib and other tyrosine
kinase inhibitors. The presence and type of KIT mutations have
been found to predict response to tyrosine kinase inhibitors in
recent studies. Patients with exon 11 mutations have better
objective response rate (63%e83.5%) and increased progression
free survival than those with exon 9 mutations (34%e47.8%) or
wild-type mutations (0%e44.6%).41e44 However, for those withimatinib resistance or intolerance, GISTs with exon 9 or wild-type
mutations have improved responses and progression-free survival
to second-line sunitinib than those with exon 11 mutations.45
6.5. Treatment for localized operable disease
The treatment strategy of GISTs varies depending on size and
tumor location. Complete surgical extirpation remains the corner-
stone of GIST management and the only curative treatment. The 5-
year overall survival rate after complete resection of GISTs is 50%e
65%.22,46,47 Every effort should be taken to ensure negative resec-
tion margins, and wide margins have not been shown to be bene-
ﬁcial. Resection can usually be accomplished with only a wedge
resection of the stomach or a segmental resection of the small
bowel. Indeed there is no evidence to suggest that more extensive
procedures prolong survival or delay recurrence.48,49 Extensive
surgery is occasionally required for large or poorly located tumors,
such as those near the gastroesophageal junction, periampullary
region, or lower rectum. When GISTs are densely adherent to
adjacent organs, en bloc resection should be performed. These
tumors should also be carefully handled to avoid tumor rupture,
which leads to a very high risk of intra-abdominal dissemination
and recurrence.34,37,38 Because GISTs rarely metastasize to lymph
nodes, formal lymphadenectomy is not necessary unless locore-
gional lymph nodes are enlarged.
6.6. Adjuvant therapy
The outcome of surgery alone have been inadequate, with up to
50% of patients developing tumor local or distant recurrence, with
a median time to recurrence of 2 years, and eventually dying from
the disease.22,46,47,50,51 GISTs are notoriously unresponsive to
chemotherapy and radiation therapy. With the success of imatinib
in the treatment of metastatic GIST, this has prompted investigation
into the potential beneﬁt of adjuvant imatinib. Imatinib mesylate is
a small molecule that inhibits activation of the KIT and PDGFa
proteins by binding to the adenosine triphosphate binding pocket
required for receptor phosphorylation and activation. The role of
adjuvant imatinib therapy is being actively investigated. The
American College of Surgeons Oncology Group (ACOSOG) Inter-
group Adjuvant GIST Study Team undertook a randomized phase III,
double-blind, placebo-controlled, multicenter trial.52 Eligible
patients had complete gross resection of a GIST at least 3 cm in size
and positive for the KIT protein by immunohistochemistry. Patients
were randomly assigned to imatinib 400mg (n¼ 359) or to placebo
(n ¼ 354) per day for 1 year after surgical resection. At a median
follow-up of 19.7 months, 30 (8%) patients in the imatinib group
and 70 (20%) in the placebo group had tumor recurrence or had
died. Imatinib signiﬁcantly improved recurrence-free survival
compared with placebo (98% vs. 83% at 1 year). Based on these
results, in 2008, imatinibwas approved at a daily dose of 400mg by
the U.S. Food and Drug Administration (FDA) as adjuvant therapy
for high-risk patients following complete surgical resection of GIST.
In 2009, the European Medicines Agency approved the use of
adjuvant imatinib for the same group of patients. However,
controversy over the duration of therapy remains.
6.7. Preoperative therapy - neoadjuvant therapy & tumor
downstaing therapy
Preoperative systemic therapy for GIST can be divided into
neoadjuvant therapy or preoperative tumor downstaging therapy.
Tumor downstaging is a new concept in the management of
unresectable malignancy. Strategies that combine the use of ima-
tinib and surgical resection have become the cornerstone of
E.C.H. Lai et al. / International Journal of Surgery 10 (2012) 334e340 337
REVIEWtreatment for these advanced GISTs. The term tumor downstaging
should be differentiated from the term neoadjuvant therapy. For
neoadjuvant therapy, the tumor is resectable, and the treatment is
given preoperatively to improve on the results of surgery. In many
patients with large or poorly localized primary tumors that would
require extensive surgery or sacriﬁce of a large amount of normal
tissue, neoadjuvant imatinib can lead to reduction in tumor size
making surgical resection to be safer and to have a better chance of
getting negative margins. For tumor downstaging, the tumor is
unresectable before treatment either because of the local extent of
the disease or because of distant metastasis.
6.8. Neoadjuvant therapy
As surgery is still the ﬁrst-line treatment for those operable
diseases, the evidence in the medical literature is limited.53e58
Results of a nonrandomized Phase II trial testing neoadjuvant/
adjuvant imatinib for primary advanced and potentially operable
metastatic/recurrent GIST, led by the Radiation Therapy Oncology
Group (RTOG), were recently published.54,55 Patients with primary
GIST (5 cm, group A) or resectable metastatic/recurrent GIST
(2 cm, group B) received neoadjuvant imatinib (600 mg/day) for
approximately 2 months and maintenance postoperative imatinib
(600 mg/day) for 2 years. Sixty-three patients were originally
entered (53 analyzable: 31 in group A and 22 in group B). Estimated
5-year progression-free survival and overall survival were 57% in
group A, 30% in group B; and 77% in group A, 68% in group B,
respectively. Amedian time to progression has not been reached for
group A and was 4.4 years for group B. In group A, in 7 of 11
patients, disease progressed >2 years from registration; 6 of 7
patients with progression had stopped imatinib before progression.
In group B, disease progressed in 10 of 13 patients >2 years from
registration; 6 of 10 patients with progressing disease had stopped
imatinib before progression. This long-term analysis suggests
a high percentage of patients experienced disease progression after
discontinuation of 2-year maintenance imatinib therapy after
surgery. Consideration should be given to studying longer treat-
ment durations in intermediate- to high-risk GIST patients.
However, until more conﬁrmatory work is performed, the use of
imatinib in the neoadjuvant setting for radiographically resectable
disease remains investigational and is not currently recommended.
The use of preoperative target therapy should be decided on a case
by case basis at centers with experience in the treatment of GIST.
6.9. Preoperative tumor downstaging therapy
There are several prerequisites for a successful neoadjuvant
therapy or tumor downstaging and salvage surgery treatment
regimen: - 1. An effective treatment which can shrink the tumor in
a signiﬁcant proportion of patients; 2. A close radiological monitor
on the tumor response to the treatment; 3. Repeated assessment by
surgeonwith a view to carry out curative resection at the right time.
As the concept of tumor downstaging followed by curative resec-
tion is new, the evidence in the medical literature is limited. This
was just highlighted by several reported series that illustrate
experience with preoperative downstaging therapy with imatinib
at various medical centers.59e61 Following maximal tumour
response, generally after 3e6 months, surgery is performed.
Despite the limited data, imatinib is the preferred initial treatment
for patients with locally advanced unresectable disease. One clear
message is that salvage surgery following tumor downstaging gives
good survival outcome and the possibility of a cure in a proportion
of patients with unresectable GIST. It gives great hope to those
patients who in the past had a dismal prognosis. The role of salvage
surgery after tumor downstaging in improving disease-free andoverall survivals in patients with unresectable GIST should be
further investigated in prospective randomized controlled trials.
7. Treatment for locally advanced inoperable disease,
metastatic disease and recurrent disease
More than half of the new cases of GIST present with advanced
or metastatic disease at diagnosis. Imatinib has revolutionized the
management of GIST. A single-patient pilot study conﬁrmed the
activity of imatinib in a patient with a rapidly progressive meta-
static GIST that was resistant to chemotherapy.62 This landmark
single-patient experience prompted Phase II and III clinical trials to
conﬁrm the efﬁcacy of imatinib in the treatment of metastatic or
unresectable GIST and rapidly expanded the global development of
imatinib.63e66 Currently, imatinib is used as the ﬁrst-line treatment
for metastatic or unresectable GIST. Imatinib therapy for unre-
sectable or metastatic GIST is typically initiated at a dosage of
400mg per day. This blockade results in a dramatic tumor response
in 50%e70% of patients with advanced GIST, associating with
a median progression-free survival and a median overall survival of
18e20 months and 51e57 months.66e68 The most common non-
hematologic toxicities in patients who received imatinib were
edema (mainly periorbital), fatigue, nausea, diarrhea, myalgia, skin
rash, headache, and abdominal/chest pain. Some of the side effects
(e.g., nausea, vomiting, edema, and rash) were reported to decrease
during the course of treatment, which may be because of the
development of tolerance. The most frequently reported hemato-
logic side effects of imatinib included anemia (dose-related) and
granulocytopenia, particularly neutropenia (independent of dose).
In 2002, the FDA approved imatinib for treating patients with KIT-
positive unresectable and/or metastatic GIST.
Two randomized, phase III studies compared imatinib given at 2
different doses: 400 mg once per day or 400 mg twice per day in
Europe and Australasia, and North America. The European Orga-
nization for Research and Treatment of Cancer (EORTC) and Aus-
tralasian Gastro-Intestinal Trials Group (AGITG) performed the
study in which 946 patients with advanced GIST were randomized
to 400 mg of imatinib once or twice per day.67 At a median follow-
up of 760 days, 263 of 473 patients (56%) allocated to imatinib once
per day had progressed compared with 235 of 473 (50%) who were
assigned to treatment of twice per day. Treatment responses were
noted equally with both regimens. Overall survival estimates were
85% at 1 year and 69% at 2 years in patients treated once per day,
and 86% at 1 year and 74% at 2 years in those treated twice per day.
Imatinib was fairly well tolerated in both arms. More dose reduc-
tions and treatment interruptions were observed with higher-dose
imatinib. The Southwest Oncology Group Intergroup trial
randomized 746 patients with advanced GIST to imatinib 400 mg
once per day or 400 mg twice per day.68 The trial reported nearly
identical response rates (40% vs. 42%). With a median follow-up of
4.5 years, a median progression-free survival was 18 months for
patients on the standard-dose arm, and 20 months for those
receiving high-dose imatinib. Median overall survivals were 55 and
51 months, respectively. There were no statistically signiﬁcant
differences in objective response rates, progression-free survival, or
overall survival. After progression on standard-dose imatinib, 33%
of patients who crossed over to the high-dose imatinib regimen
achieved either an objective response or stable disease. There were
more severe toxicities noted on the high-dose imatinib arm. Both
studies showed equivalent response rates and overall survival at
both dose levels. A higher dose of imatinib was associated with
more side effects than a lower dose in both studies. Both the studies
conﬁrmed the starting dose of 400 mg per day for most patients.
The results of the meta-analysis of 1640 patients from both trials
showed a small progression-free survival advantage of high-dose
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no overall survival advantage.69 Based on the current evidence, two
groups beneﬁted from the treatment with 400 mg twice daily of
imatinib: (1) patients with disease progression on standard-dose
therapy, and (2) patients whose tumor harbors an exon 9 muta-
tion in KIT.
The duration of imatinib therapy in advanced GIST has been
evaluated in two French Sarcoma Group phase III randomized
studies separately evaluating outcomes of patients with responding
or stable disease to interruption of treatment after 1 year and after
3 years of imatinib, respectively.70,71 The ﬁrst study, 58 patients
with response or stable disease under imatinib who reached more
than 1 year of follow-up were randomized between May 2003 and
April 2004 to 32 and 26 patients in the interruption and continu-
ation arms, respectively.70 In October 2005, eight of 26 patients in
the continuation group and 26 of 32 patients in the interruption
group had documented disease progression. Twenty-four of 26
patients with documented progression in the interruption arm
responded to imatinib reintroduction. No differences in overall
survival or imatinib resistance were observed between the two
arms. In another study, 50 patients with non-progressive disease
who had received 3 years of treatment with imatinib were
randomly assigned between June, 2005, and May, 2007 to the
interruption and continuation arms, 25 patients in each group.71
After a median follow-up of 35 months, 2-year progression-free
survival was 80% in the continuation group and 16% in the inter-
ruption group. For these reasons, imatinib treatment is usually
continued indeﬁnitely in the absence of disease progression or
unacceptable toxicity, since treatment interruption is generally
followed by relatively rapid tumor progression in virtually all
patients.
Progression on ﬁrst-line therapy with imatinib on GIST is caused
by either initial resistance or more often a secondary mutation in
tyrosine kinases KIT or PDGFR. The standard approach in the case of
tumor progression on 400 mg once per day is to increase the
imatinib dose to 400 mg twice per day as permitted by toxicity.
Around one-third of patients with unresectable and/or metastatic
GIST, who fail on 400 mg per day of imatinib, show response or
have stable disease with the escalated doses.72 Those who have
progressive diseases, or are intolerant of imatinib, are treated with
a second-line tyrosine kinase inhibitor, sunitinib malate (Pﬁzer,
New York, NY) at a dose of 50mg per day in a 4-weeks-on/2-weeks-
off regimen. Sunitinib is a small molecule, oral, multi-targeted
tyrosine kinase inhibitor with potent anti-angiogenic and anti-
tumor activities, targets receptors of KIT, vascular endothelial
growth factor receptor (VEGF1, 2, 3), platelet-derived growth factor
(PDGFA and B), Fms-like tyrosine kinase-3 (FLT3), and a receptor
encoded by ret proto-oncogene (RET). Demetri and colleagues
published their double-blind randomized, phase III trial comparing
sunitinib in 207 patients and placebo in 105 patients who had
advanced GIST resistant to or intolerant of previous treatment with
imatinib.73 The median time to tumor progression was 27.3 weeks
in patients receiving sunitinib and 6.4 weeks in those on placebo.
The therapy was reasonably well tolerated, and the most common
treatment-related adverse events were fatigue, diarrhea, and skin
discoloration. In 2006, the FDA approved second-line use of suni-
tinib in patients with advanced GIST who fail (or are intolerant of)
imatinib therapy. In another study, progression-free survival was
signiﬁcantly longer for patients with primary KIT exon 9 mutations
(19.4 vs. 5.1 months) or with a wild-type genotype (19 vs. 5.1
months) than for those with KIT exon 11 mutations.45 Alternatively,
a regimen consisting of a daily dose of 37.5 mg may be used. A
phase II study evaluated whether continuous daily dosing at
a lower dose of 37.5 mg per day would be potentially as efﬁcacious
and less toxic than the 4/2 schedule.74 The overall clinical beneﬁtrate was 53% (13% experienced partial responses and 40% stable
disease). The median progression-free survival was 34 weeks and
the median overall survival at the time of analysis was 107 weeks.
No new adverse events were apparent compared with the
approved intermittent dosing schedule. The results of this study
suggest that continuous daily dosing appears to be an effective
alternative dosing strategy with acceptable safety for patients.8. Conclusion
The last decade marked an important era in the history of GIST,
culminating from the advancement of diagnosis of GIST and our
understanding of its pathogenesis, to the development of risk
prognostic score and consequently, inﬂuencing treatment strate-
gies. This translation of laboratory successes into biologically rele-
vant therapeutics dramatically improves patient outcomes. Future
studies should focus on how to integrate the molecular therapy
well with surgery for the management of operable or inoperable
GIST. Large multi-institutional clinical trials to investigate the efﬁ-
cacy of imatinib as adjuvant or neoadjuvant therapy for GISTs are
now required.
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